Cash constraints are forcing Corvus Pharmaceuticals to clip the wings of its lead candidate. Rather than advance on multiple fronts, the biotech is focusing on cancers including T-cell lymphoma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback